Mohamed Zaki serves as the Chief Medical Officer at ADC THERAPEUTICS SA, a position he has held since joining the company in 2020. With an extensive background in oncology and hematology, Dr. Zaki brings a wealth of experience to his role at ADC THERAPEUTICS SA. He earned his medical degree from Cairo University and completed his residency in Internal Medicine at the University of Medicine and Dentistry of New Jersey. Dr. Zaki further honed his expertise through a fellowship in Hematology/Oncology at the University of Texas MD Anderson Cancer Center, one of the world's most respected cancer treatment and research institutions. Prior to his appointment at ADC THERAPEUTICS SA, Dr. Zaki held several significant positions in the pharmaceutical and biotech industries. He served as the Chief Medical Officer at Tracon Pharmaceuticals, where he played a pivotal role in advancing the company's oncology pipeline. Before that, he was the Senior Vice President of Clinical Development at Spectrum Pharmaceuticals, where he led the clinical development of multiple cancer therapies. Dr. Zaki's career also includes time at Eisai, where he contributed to the development of oncology drugs, and at Novartis, where he worked on hematology projects. His diverse experience across these organizations has equipped him with a deep understanding of drug development and clinical trial management. In his current role at ADC THERAPEUTICS SA, Dr. Zaki is responsible for overseeing the clinical development of the company's portfolio of antibody-drug conjugates (ADCs) targeting various cancers. His leadership has been instrumental in advancing several key programs, including the development of loncastuximab tesirine, which has received accelerated approval from the FDA for the treatment of relapsed or refractory large B-cell lymphoma. Dr. Zaki's strategic vision and dedication to improving cancer treatment outcomes continue to drive ADC THERAPEUTICS SA's mission to deliver innovative therapies to patients in need.